Filing summary
Entity note: The supplied filing is Vital Therapies, Inc.’s Form 10-Q, not a filing identified as IMMUNIC, INC. It covers the quarter ended September 30, 2017, and is dated October 25, 2017. The financial statements are unaudited.
Business context and reporting period
Vital Therapies was a clinical-stage biotherapeutics company developing ELAD, an extracorporeal human liver-cell therapy for acute liver failure. It reported no revenue from planned principal operations. Its sole product candidate was in Phase 3 testing for severe alcoholic hepatitis (VTL-308). The prior Phase 3 VTI-208 trial failed to meet its primary and secondary endpoints.
Key financial metrics
| Metric | Q3 2017 / September 30, 2017 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $9.689 million for Q3; $29.151 million for nine months | $7.469 million and $21.184 million, respectively, in 2016 |
| General and administrative expense | $2.950 million for Q3; $8.724 million for nine months | $2.770 million and $8.257 million, respectively, in 2016 |
| Net loss | $12.481 million for Q3; $37.490 million for nine months | $10.178 million and $29.235 million, respectively, in 2016 |
| Net loss per share, basic and diluted | $0.30 for Q3; $0.96 for nine months | $0.32 and $0.94, respectively, in 2016 |
| Operating cash flow | $(30.477) million for nine months | $(26.672) million in 2016 |
| Cash and cash equivalents | $66.391 million | $59.991 million at December 31, 2016 |
| Total assets / current liabilities | $70.358 million / $8.234 million | $64.026 million / $5.480 million at December 31, 2016 |
| Accumulated deficit | $281.365 million | $243.825 million at December 31, 2016 |
Operating margins are not meaningful because the company reported no revenue and incurred operating losses. The balance sheet lists $46,000 of long-term liabilities; the filing does not identify borrowings as a material financing source.
Material changes versus prior periods
- Q3 operating expenses rose 23% year over year to $12.639 million; nine-month expenses rose 29% to $37.875 million. R&D drove most of the increase, reflecting higher clinical-trial, manufacturing, enrollment-support and potential BLA-preparation costs.
- Q3 net loss increased from $10.178 million to $12.481 million; nine-month net loss increased from $29.235 million to $37.490 million. Nine-month loss per share increased to $0.96 from $0.94.
- Cash increased by $6.400 million during the first nine months, principally because $37.529 million of net proceeds from the March 2017 public offering exceeded operating and investing cash use. Common shares outstanding rose to 42.207 million from 32.143 million at year-end 2016.
- Accrued expenses rose to $7.167 million from $4.656 million, largely reflecting clinical-trial accruals.
Outlook, risks and unusual items
- As of October 24, 2017, management reported 118 subjects enrolled in VTL-308 and 45 sites open. The trial was expected to enroll at least 150 subjects, with top-line data anticipated in Q3 2018.
- Management estimated that September 30 cash would fund operations through Q1 2019, beyond the expected trial data announcement, assuming limited BLA activity and no significant commercial infrastructure build. This is a forward-looking estimate; the company said additional capital may be needed and had no committed external funding source.
- The company completed a March 2017 follow-on offering that generated $37.5 million in net proceeds. At September 30, $113.1 million remained available under its shelf registration statement, including $62.8 million under the ATM facility.
- Key risks include VTL-308 failing to demonstrate efficacy, possible need for another pivotal trial, enrollment delays, regulatory and manufacturing hurdles, dependence on single-source suppliers, and inability to raise capital on acceptable terms. The earlier VTI-208 Phase 3 trial failed its primary and secondary endpoints.
- There were no material litigation matters identified. Management reported effective disclosure controls as of September 30 and no material change in internal control over financial reporting during the period.
- The company adopted accounting guidance recognizing stock-option forfeitures as they occur, recording a $50,000 cumulative-effect adjustment to additional paid-in capital and accumulated deficit.
Important facts for investors to verify
- Confirm the issuer: this source document names Vital Therapies, Inc., whereas the request names IMMUNIC, INC.
- Check subsequent VTL-308 enrollment, trial results, regulatory interactions and whether the anticipated Q3 2018 data timing changed.
- Assess cash burn and financing needs against management’s Q1 2019 runway estimate, including any changes in trial or BLA spending.
- Review the potential dilution from future equity issuance and the remaining shelf and ATM capacity.
- Evaluate whether the VTL-308 design and results can support regulatory approval, given the prior Phase 3 failure and the possibility regulators may require confirmatory evidence.